Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission. The Fukouka Bone Marrow Transplant Group.
We conducted a clinical trial to increase the chemosensitivity of residual leukemic cells by combining G-CSF to marrow-ablative chemotherapy, including cytosine arabinoside (Ara-C), and facilitated by autologous blood cell transplantation (ABCT) for treatment of acute myelogenous leukemia (AML) in first complete remission. A total of 16 patients were consecutively treated with granulocyte colony-stimulating factor (G-CSF)-combined high-dose chemotherapy (busulfan, etoposide and Ara-C) followed by autotransplantation of peripheral blood progenitor cells, which had been collected after the consolidation chemotherapy. At a median follow-up time of 44.5 months, the probability of 5-year event-free survival was 74.5% with only three leukemic relapses. This preliminary observation suggests the effectiveness of G-CSF-combined conditioning and ABCT as a post-remission therapy for AML.
Harada
M
M
Second Department of Internal Medicine, Okayama University Medical School, Japan.
Akashi
K
K
Hayashi
S
S
Eto
T
T
Takamatsu
Y
Y
Teshima
T
T
Hirota
Y
Y
Taniguchi
S
S
Nagafuji
K
K
Mizuno
S
S
Gondo
H
H
Niho
Y
Y
D000293:Adolescent; D000328:Adult; D000368:Aged; D016465:Bone Marrow Purging; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012074:Remission Induction / Q000379:methods; D014182:Transplantation, Autologous
D016179:Granulocyte Colony-Stimulating Factor